Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Brii Biosciences Taps OpenBench AI Platform to Accelerate Drug Discovery

Fineline Cube Dec 13, 2025
Company Deals

GSK Terminates Ideaya Synthetic Lethality Partnership, Returns Two Clinical Programs

Fineline Cube Dec 13, 2025
Company Deals

B&K Corporation Debuts on HKEX in $900M IPO Backed by Burn Drug Pipeline

Fineline Cube Dec 13, 2025
Company Deals

OBT and GSK Forge Multi-Target Cancer Collaboration Using OGAP Platform

Fineline Cube Dec 13, 2025
Company Deals

Insilico Licenses AI‑Designed ISM4808 PHD Inhibitor to TaiGen in Two‑Digit Million Dollar Greater China Deal

Fineline Cube Dec 13, 2025
Policy / Regulatory

NHSA 2025 Drug Lists Add 114 Medical Insurance Drugs, 19 Commercial

Fineline Cube Dec 8, 2025
Company Drug

Sino Biopharm’s Culmerciclib Wins NMPA Approval as First CDK2/4/6 Inhibitor for Breast Cancer

Fineline Cube Dec 13, 2025
Company Drug

Lobemilast (Y‑3) NDA Accepted by NMPA as First Multi‑Target Stroke Neuroprotectant

Fineline Cube Dec 12, 2025
Company Deals

HitGen Inc. Forms Strategic Partnership for New Drug Research and Development

Fineline Cube Jun 19, 2022

China-based HitGen Inc. (SHA: 688222) announced the establishment of a strategic partnership with compatriot firm...

Company Drug

Yabao Pharmaceutical’s YBSW015 Gets Australian Ethical Approval for COVID-19 Trial

Fineline Cube Jun 16, 2022

China-based Yabao Pharmaceutical Group Co., Ltd (SHA: 600351) has announced that it has received clinical...

Drug

Suzhou Zelgen’s JAK Inhibitor Jacktinib Gets NMPA Green Light for COVID-19 Trial

Fineline Cube Jun 16, 2022

China-based Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) has announced that it has received approval...

Company Drug

Sichuan Kelun’s KL340399 Wins NMPA Approval for Solid Tumor Trials

Fineline Cube Jun 16, 2022

China-based Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422) announced receiving clinical trial approval from the...

Company Deals

WinHealth Pharma and Ferring Partner to Co-Promote Pentasa in China

Fineline Cube Jun 16, 2022

China-based Hong Kong WinHealth Pharma Group Ltd has entered into a new partnership with Switzerland-headquartered...

Company Deals

WuXi ATU Partners with Wugen to Accelerate NK Cell Therapy Development

Fineline Cube Jun 16, 2022

WuXi ATU, the gene and cell therapy-focused CTDMO unit of WuXi Apptec (SHA: 603259, HKG:...

Company Drug

Jiangsu Hengrui Medicine’s SHR4640 Receives NMPA Approval for Gout Trial

Fineline Cube Jun 16, 2022

China-based Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) has announced receiving approval from the National...

Company Drug

Beijing Aosaikang’s ASKG315 Receives NMPA Approval for Solid Tumor Trial

Fineline Cube Jun 16, 2022

Beijing Aosaikang Pharmaceutical Co., Ltd (SHE: 002755) announced that its clinical trial application for ASKG315,...

Company Deals

Jacobson Pharma Leads HKD 6 Million JV for Specialty Drug Distribution

Fineline Cube Jun 16, 2022

China-based Jacobson Pharma Corporation (HKG: 2633), Ban Loong Holdings Ltd (HKG: 0030), and JBM (Healthcare)...

Company Drug

Hansoh Pharmaceutical’s Ameile Accepted for UK Regulatory Review

Fineline Cube Jun 16, 2022

China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) announced that a Marketing Authorization Application (MAA)...

Company Deals

MegaRobo Secures USD 300 Million in Series C Round Led by Goldman Sachs

Fineline Cube Jun 16, 2022

Beijing-based MegaRobo Technologies, a company applying robotics and artificial intelligence (AI) in the life sciences...

Policy / Regulatory

China Issues Monkeypox Diagnosis Guidelines Amid Global Outbreaks

Fineline Cube Jun 16, 2022

China’s National Health Commission (NHC) has formulated and released the “Monkeypox Diagnosis and Treatment Guidelines”...

Company Deals

Quoin Pharmaceuticals Partners with WinHealth for Rare Disease Treatments in Greater China

Fineline Cube Jun 16, 2022

US-based rare disease specialist Quoin Pharmaceuticals Ltd (NASDAQ: QNRX) announced a licensing and distribution agreement...

Legal / IP Policy / Regulatory

US Bipartisan Bill Seeks to Regulate Investments in Chinese High-Tech Firms

Fineline Cube Jun 16, 2022

US senators are preparing a bipartisan bill that would require US investors targeting Chinese high-tech...

Company Drug

Alphamab Oncology Doses First Patient in Phase I Trial for PD-L1/OX40 Bispecific Antibody KN052

Fineline Cube Jun 15, 2022

China-based Alphamab Oncology (HKG: 9966) has announced the dosing of the first patient in a...

Company Drug

Walvax Biotechnology Halts EV71 Vaccine Development Amid Changing Disease Trends

Fineline Cube Jun 15, 2022

China’s Walvax Biotechnology Co., Ltd (SHE: 300142) has announced the decision to terminate a clinical...

Company Drug

Jiangsu Hengrui Medicine’s Hetrombopag Olamine Receives FDA Orphan Drug Designation for ITP

Fineline Cube Jun 15, 2022

China-based Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) has announced that it has received orphan...

Company Legal / IP

WuXi AppTec Faces Shareholder Divestment of Up to 3% Stake

Fineline Cube Jun 15, 2022

China-based Contract Research Organization (CRO) WuXi AppTec Co., Ltd (SHA: 603259, HKG: 2359) has disclosed...

Company Drug

Zai Lab Ltd Makes FcRn Antagonist Efgartigimod Available for Myasthenia Gravis Treatment

Fineline Cube Jun 15, 2022

Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) has announced the availability of efgartigimod, the world’s...

Company Drug

Bristol-Myers Squibb Launches Reblozyl in China for β-Thalassemia Treatment

Fineline Cube Jun 15, 2022

US pharmaceutical giant Bristol-Myers Squibb (BMS; NYSE: BMY) has announced the commercial launch of its...

Posts pagination

1 … 592 593 594 … 596

Recent updates

  • Brii Biosciences Taps OpenBench AI Platform to Accelerate Drug Discovery
  • GSK Terminates Ideaya Synthetic Lethality Partnership, Returns Two Clinical Programs
  • B&K Corporation Debuts on HKEX in $900M IPO Backed by Burn Drug Pipeline
  • OBT and GSK Forge Multi-Target Cancer Collaboration Using OGAP Platform
  • Lilly to Invest Over $6 Billion in Alabama GLP‑1 Manufacturing Hub for Orforglipron
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Brii Biosciences Taps OpenBench AI Platform to Accelerate Drug Discovery

Company Deals

GSK Terminates Ideaya Synthetic Lethality Partnership, Returns Two Clinical Programs

Company Deals

B&K Corporation Debuts on HKEX in $900M IPO Backed by Burn Drug Pipeline

Company Deals

OBT and GSK Forge Multi-Target Cancer Collaboration Using OGAP Platform

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.